PMC:7195088 / 57711-58841
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1721 | 18-26 | Species | denotes | patients | Tax:9606 |
1722 | 513-521 | Species | denotes | patients | Tax:9606 |
1723 | 582-590 | Species | denotes | Patients | Tax:9606 |
1724 | 557-570 | Chemical | denotes | dexamethasone | MESH:D003907 |
1725 | 617-630 | Chemical | denotes | dexamethasone | MESH:D003907 |
1726 | 818-831 | Chemical | denotes | dexamethasone | MESH:D003907 |
1727 | 1083-1096 | Chemical | denotes | dexamethasone | MESH:D003907 |
1728 | 3-17 | Disease | denotes | critically ill | MESH:D016638 |
1729 | 76-100 | Disease | denotes | inflammation–coagulation | MESH:D001778 |
1730 | 136-171 | Disease | denotes | acute respiratory distress syndrome | MESH:D012128 |
1731 | 173-177 | Disease | denotes | ARDS | MESH:D012128 |
1732 | 246-250 | Disease | denotes | ARDS | MESH:D012128 |
1733 | 342-354 | Disease | denotes | inflammation | MESH:D007249 |
1734 | 527-531 | Disease | denotes | ARDS | MESH:D012128 |
1735 | 943-952 | Disease | denotes | mortality | MESH:D003643 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T91 | 385-390 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
T92 | 604-607 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T46 | 385-390 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
T47 | 604-607 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T99 | 142-162 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T328 | 76-88 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T329 | 136-171 | Disease | denotes | acute respiratory distress syndrome | http://purl.obolibrary.org/obo/MONDO_0006502 |
T330 | 142-171 | Disease | denotes | respiratory distress syndrome | http://purl.obolibrary.org/obo/MONDO_0009971 |
T331 | 173-177 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T332 | 246-250 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T333 | 342-354 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T334 | 527-531 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T318 | 205-206 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T319 | 295-296 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T320 | 385-390 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
T321 | 475-476 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T322 | 604-607 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
T323 | 749-750 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T324 | 916-917 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T98872 | 28-43 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
T54230 | 224-238 | Chemical | denotes | corticosteroid | http://purl.obolibrary.org/obo/CHEBI_50858 |
T17441 | 557-570 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
T90766 | 617-630 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
T70095 | 818-831 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
T42283 | 832-837 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T49874 | 858-863 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T47088 | 873-878 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T59830 | 973-978 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T57744 | 1083-1096 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
T54060 | 1097-1102 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T69982 | 1119-1124 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T25 | 76-88 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T26 | 89-100 | http://purl.obolibrary.org/obo/GO_0050817 | denotes | coagulation |
T27 | 342-354 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T425 | 0-204 | Sentence | denotes | In critically ill patients, corticosteroids may be provided to decrease the inflammation–coagulation–fibroproliferation observed during acute respiratory distress syndrome (ARDS) [[58], [59], [60], [61]]. |
T426 | 205-474 | Sentence | denotes | A meta-analysis on corticosteroid use in ARDS including eight controlled studies reported a significant reduction in markers of systemic inflammation, pulmonary and extrapulmonary organ dysfunction scores, duration of mechanical ventilation and ICU length of stay [62]. |
T427 | 475-581 | Sentence | denotes | A recent multicentre RCT included 277 patients with ARDS to assess the effects of dexamethasone treatment. |
T428 | 582-728 | Sentence | denotes | Patients in the study arm received dexamethasone 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. |
T429 | 729-1008 | Sentence | denotes | This study reported a significant reduction in duration of mechanical ventilation in the dexamethasone group than in the control group (between-group difference 4.8 days, p < 0.0001) and a significant reduction in mortality at 60 days (between-group difference −15.3%, p 0.0047). |
T430 | 1009-1130 | Sentence | denotes | The proportion of adverse events did not differ significantly between the dexamethasone group and the control group [63]. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32360444-22088618-22369798 | 181-183 | 22088618 | denotes | 58 |
32360444-7587435-22369799 | 187-189 | 7587435 | denotes | 59 |
32360444-11934726-22369800 | 193-195 | 11934726 | denotes | 60 |
32360444-21983371-22369801 | 199-201 | 21983371 | denotes | 61 |
32360444-19325471-22369802 | 470-472 | 19325471 | denotes | 62 |
32360444-32043986-22369803 | 1126-1128 | 32043986 | denotes | 63 |